Recruiting
Phase 2
Phase 3

Glofitamab with Chemoimmunotherapy

Sponsor:

National Cancer Institute (NCI)

Code:

NCT07724457

Conditions

Recurrent Burkitt Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Refractory Burkitt Lymphoma

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Biopsy

Carboplatin

Computed Tomography

Cyclophosphamide

Study Details

Brief summary:

This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Glofitamab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Obinutuzumab and rituximab are also monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cytarabine and ifosfamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab with standard of care chemotherapy may work well for the treatment of newly diagnosed, relapsed or refractory Burkitt and high grade (double hit) B- cell lymphomas.

Conditions

Recurrent Burkitt Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Refractory Burkitt Lymphoma

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Study ID

NCT07724457

Start date

Jul 27, 2027

Status verified date

Oct, 2026

Completion date

Nov 1, 2033

Anticipated

Primary completion date

Nov 1, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • BURKITT LYMPHOMA (BL) COHORT 1: Histologically confirmed Burkitt lymphoma by International Consensus Classification criteria. Patients with Burkitt lymphoma must have one or more of the following adverse risk factors at diagnosis:

  • Stage III or IV disease
  • Elevated lactate dehydrogenase (LDH) greater than institutional upper limit of normal (ULN)
  • Tumor mass ≥ 7 cm
  • BL COHORT 1: No prior treatment except for pre-phase chemotherapy, pre-phase corticosteroids, or one cycle of chemotherapy as described below.

  • Pre-phase chemotherapy with corticosteroids or cyclophosphamide/prednisone is permitted prior to enrollment.
  • One cycle of prior chemotherapy (for example, cyclophosphamide, doxorubicin, vincristine and prednisone \[CHOP\], Polatuzumab-cyclophosphamide doxorubicin and prednisone \[CHP\], cyclophosphamide, vincristine, doxorubicin and methotrexate \[CODOXM\], or etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin \[EPOCH\] \[with or without rituximab\]) may be administered no more than 21 days prior to enrollment.
  • Patients enrolling on study after one cycle of prior anthracycline containing therapy will start the study therapy in cycle 2 and cycle 2 must occur no later than 22-36 days after the start of cycle 1. (If feasible, cycle 2 should start on day 22, but +14 days is permitted to permit recovery from toxicity in cycle 1)
  • BL COHORT 1: Age ≥ 18 years
  • BL COHORT 1: Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • BL COHORT 1: Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (unless attributable to lymphoma)
  • BL COHORT 1: Platelet count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • BL COHORT 1: Calculated (Calc.) creatinine clearance ≥ 50 mL/min (unless attributable to lymphoma)
  • BL COHORT 1: Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Total bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's syndrome) (unless attributable to lymphoma)
  • BL COHORT 1: International normalization ratio (INR) OR prothrombin time (PT) > 1.5 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) > 1.5 x institutional ULN (unless attributable to lymphoma)
  • BL COHORT 1: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of childbearing potential only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

  • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • BL COHORT 1: Patients with prior malignancy or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • BL COHORT 1: Patients with HIV are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • BL COHORT 1: Patients with a history of hepatitis B who are hepatitis B (HepB) surface antigen (Ag) positive and/or HepB core antibody (Ab) positive with undetectable Hep B viral load who start suppressive antiviral therapy prior to chemotherapy are eligible
  • BL COHORT 1: Patients with a history of hepatitis C infection that have been treated for hepatitis C virus (HCV) and have an undetectable HCV viral load are eligible
  • BL COHORT 1: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as ejection fraction of ≥ 45%
  • BL COHORT 1: Patients with CSF/leptomeningeal involvement at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • BL COHORT 1: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • BL COHORT 1: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • BL COHORT 1: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • BL COHORT 1: Patients with a prior history of hemophagocytic lymphohistiocytosis (HLH) are NOT eligible
  • BL COHORT 1: Patients with a history of autoimmune disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.

However, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 or type 2 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers < 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.

Lastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible.

  • BL COHORT 1: Patients with a history of progressive multifocal leukoencephalopathy (PML) are NOT eligible
  • BL COHORT 1: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 day (D) 1 of study treatment are NOT eligible
  • DOUBLE HIT LYMPHOMA (DHL) COHORT 2: Histologically confirmed high grade/double hit B-cell lymphoma with MYC and BCL2 translocations by International Consensus Classification (ICC) or World Health Organization (WHO) criteria. Fluorescence in situ hybridization (FISH) For MYC and BCL2 translocations must be performed by the referring site and must be positive for translocations of BOTH MYC and BCL2. Patients found to have BCL6 translocations in addition to BOTH MYC and BCL2 (so called "triple hit lymphoma") are eligible
  • DHL COHORT 2: Stage II-IV disease per Lugano staging classification
  • DHL COHORT 2: No prior treatment except for pre-phase chemotherapy, pre-phase corticosteroids, or one cycle of chemotherapy as described below.

  • Pre-phase chemotherapy with corticosteroids or cyclophosphamide/prednisone is permitted prior to enrollment.
  • One cycle of prior chemotherapy (for example, CHOP, Polatuzumab-CHP, or EPOCH (with or without Rituximab)) may be administered no more than 21 days prior to enrollment.
  • Patients enrolling on study after one cycle of prior anthracycline containing therapy will start the study therapy in cycle 2 and cycle 2 must occur no later than 22-36 days after the start of cycle 1. (If feasible, cycle 2 should start on day 22, but +14 days is permitted to permit recovery from toxicity in cycle 1)
  • DHL COHORT 2: Age ≥ 18 years
  • DHL COHORT 2: ECOG performance status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • DHL COHORT 2: Absolute neutrophil count (ANC) ≥ 1,000/mm\^ 3 (unless attributable to lymphoma)
  • DHL COHORT 2: Platelet Count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • DHL COHORT 2: Calc. Creatinine Clearance ≥ 50 mL/min (unless attributable to lymphoma)
  • DHL COHORT 2: AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: Total Bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • DHL COHORT 2: INR OR PT > 1.5 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: PTT or aPTT > 1.5 x institutional ULN (unless attributable to lymphoma)
  • DHL COHORT 2: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of childbearing potential only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

  • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • DHL COHORT 2: Patients with prior malignancy or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • DHL COHORT 2: Patients with HIV are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • DHL COHORT 2: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who start suppressive antiviral therapy prior to chemotherapy are eligible
  • DHL COHORT 2: Patients with a history of hepatitis C infection that have been treated for HCV and have an undetectable HCV viral load are eligible
  • DHL COHORT 2: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as ejection fraction of ≥ 45%
  • DHL COHORT 2: Patients with CSF/leptomeningeal involvement at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • DHL COHORT 2: Corticosteroid use: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • DHL COHORT 2: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • DHL COHORT 2: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy, or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • DHL COHORT 2: Patients with a prior history of HLH are NOT eligible
  • DHL COHORT 2: Patients with a history of autoimmune disease (including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Guillain-Barre syndrome, or multiple sclerosis) are NOT eligible.

However, patients with autoimmune related hypothyroidism on a stable dose of thyroid replacement hormone, patients with a history of lymphoma related immune thrombocytopenic purpura or hemolytic anemia, and patients with type 1 or type 2 diabetes on a stable insulin regimen are eligible to enroll. In addition, patients with eczema, lichen simplex chronicus, or vitiligo with dermatologic manifestations only may also enroll if the rash covers < 10% of body surface area and the disease is well controlled and requires only topical corticosteroids.

Lastly, patients treated with prior immunotherapeutic agents with a history of any grade 3 events (except for grade 3 endocrinopathy managed with replacement therapy) or grade 1-2 events that did not resolve to baseline with treatment discontinuation are NOT eligible

  • DHL COHORT 2: Patients with a history of PML are NOT eligible
  • DHL COHORT 2: Patients who have received live, attenuated vaccines within 4 weeks prior to cycle 1 D1 of study treatment are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Histologically confirmed Burkitt lymphoma by International Consensus Classification criteria
  • RELAPSED BL AND HGL COHORT 3: Patients must have relapsed or refractory disease after at least one prior treatment with chemotherapy or chemoimmunotherapy.

  • Prior radiotherapy in addition or in conjunction with prior chemotherapy is permitted.
  • Patients who have previously received a bispecific antibody (BsAb) are NOT eligible. However, patients enrolled to the standard arms on cohorts 1 and 2 of this trial who did not receive glofitamab and have relapsed or refractory disease are eligible to enroll on cohort 3.
  • Prior treatment with systemic immunotherapeutic agents including antibody drug conjugates, radio-immunoconjugates, or immune/cytokine direct therapy must have occurred within 3 weeks or five half-lives of the drug, whichever is shorter
  • RELAPSED BL AND HGL COHORT 3: Age ≥ 18 years
  • RELAPSED BL AND HGL COHORT 3: ECOG Performance Status ≤ 2. ECOG performance status of 3 is permitted if related to lymphoma
  • RELAPSED BL AND HGL COHORT 3: Absolute Neutrophil Count (ANC) ≥ 1,000/mm\^3 (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Platelet Count ≥ 75,000/mm\^3 (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Calc. Creatinine Clearance ≥ 50 mL/min (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Total bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: INR OR PT > 1.5 x institutional ULN (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: PTT or aPTT > 1.5 x institutional ULN (unless due to Gilbert's Syndrome) (unless attributable to lymphoma)
  • RELAPSED BL AND HGL COHORT 3: Not pregnant and not nursing, and willingness to remain abstinent or use contraception because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. For women of childbearing potential only, a negative pregnancy test done less than or equal to 28 days prior to registration is required

  • Female participants of childbearing potential must also agree to remain abstinent (refrain from heterosexual intercourse) or use contraception and agree to refrain from donating eggs. Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment and for at least 18 months after obinutuzumab, 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Women must refrain from donating eggs during this same period
  • Male participants must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agree to refrain from donating sperm. With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (if required for cytokine release syndrome), whichever is longer. Male participants must refrain from donating sperm during this same period
  • RELAPSED BL AND HGL COHORT 3: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (i.e. anthracycline dosing that will exceed recommended lifetime maximum dosing) are eligible for this trial
  • RELAPSED BL AND HGL COHORT 3: Patients with HIV are eligible but must be on effective anti-retroviral therapy, with undetectable viral load within 6 months of enrollment
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of hepatitis B who are HepB surface Ag positive and/or HepB core Ab positive with undetectable Hep B viral load who are taking suppressive antiviral therapy are eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of hepatitis C infection that have been treated for HCV and have an undetectable HCV viral load are eligible
  • RELAPSED BL AND HGL COHORT 3: No active ischemic heart disease or congestive heart failure, AND adequate cardiac function defined as ejection fraction of ≥ 45%
  • RELAPSED BL AND HGL COHORT 3: Patients with CSF/leptomeningeal involvement at diagnosis are eligible. Patients with parenchymal brain involvement at diagnosis are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Corticosteroid use: Patients requiring > 10 mg/day of prednisone or equivalent, for the treatment of conditions other than the control of lymphoma related symptoms, are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with major surgery within 4 weeks other than for diagnosis of lymphoma are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with known active infections, or reactivation of a latent infection (excluding fungal infections of nail bed, hepatitis B on suppressive therapy, or treated hepatitis C) requiring hospitalization or treatment with IV antibiotics within 4 weeks of study treatment are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a prior history of HLH are NOT eligible
  • RELAPSED BL AND HGL COHORT 3: Patients with a history of autoimmune disease (includi

Study Design

Enrollment

271 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Cohort 1 arm 2 RCODOXM/RIVAC or DA-REPOCH and glofitamab)

See Detailed Description

experimental: Cohort 1, arm 1 RCODOXM/RIVAC or DA-REPOCH)

See Detailed Description.

experimental: Cohort 2 arm 3 (DA-REPOCH)

Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5.

Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments.

Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.

experimental: Cohort 2 arm 4 (DA-REPOCH and glofitamab)

Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6.

Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab.

Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab.

Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study.

experimental: Cohort 3 (RICE and glofitamab)

See Detailed Description

Interventions

Biospecimen Collection

Undergo blood and/or cerebrospinal fluid collection

Bone Marrow Biopsy

Undergo bone marrow biopsy

Carboplatin

Given IV

Computed Tomography

Undergo CT scan

Cyclophosphamide

Given IV

Cytarabine

Given IV or IT

Doxorubicin

Given IV

Etoposide

Given IV

Glofitamab

Given IV

Ifosfamide

Given IV

Lumbar Puncture

Undergo lumbar puncture

Magnetic Resonance Imaging

Undergo MRI

Methotrexate

Given IV or IT

Obinutuzumab

Given IV

Positron Emission Tomography

Undergo PET scan

Prednisone

Given PO

Rituximab

Given IV

Rituximab and Hyaluronidase Human

Given SC

Survey Administration

Ancillary studies

Vincristine

Given IV

Primary outcome measure

  • Progression free survival (PFS) (cohort 1) (phase II) [ Time Frame: from randomization to the time of documented disease progression or death due to any cause ]
  • PFS (cohort 1) (phase III) [ Time Frame: At 24 months ]
  • PFS (cohort 2) (phase II) [ Time Frame: From randomization to the time of documented disease progression or death due to any cause, up to 5 years ]
  • PFS (cohort 2) (phase III) [ Time Frame: At 24 months ]
  • Overall survival (cohort 3) [ Time Frame: At 12 months after start of treatment ]

Central Contacts and Locations

Locations

Alliance for Clinical Trials in Oncology

Recruiting

Chicago, Illinois, United States, 60606

Contacts

Kristie A. Blum

kablum@emory.edu

Principal Investigator:

Kristie A. Blum

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Nov 17, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.